MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$5,378K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Intangible asset impairment char...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Other segment items
Selling expenses
Purchases of marketable securiti...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
219,058
207,705
211,572
192,103
Cost of revenues
33,669
23,391
23,007
18,965
Selling expenses
68,910
66,278
64,297
58,386
Marketing expenses
23,881
20,697
18,888
18,672
General and administrative expenses
40,846
38,198
37,154
31,746
Acquisition-related expenses
-
-
2,051
70,874
ONAPGO
515
261
270
352
SPN820
2,968
1,849
2,002
1,111
SPN817
6,943
16,557
3,838
4,872
SPN443
1,046
-
-
-
Qelbree
2,217
2,364
1,606
3,168
ZURZUVAE
73
82
760
1,385
Early Stage Program And Other
5,102
6,565
9,061
5,173
Total external development program expenses
18,864
27,678
17,537
16,061
Internal employee-related expenses
10,599
11,760
10,290
13,305
Total research and development expenses
29,463
39,438
27,827
29,366
Other segment items
80,660
21,996
42,453
9,211
Net earnings (loss)
-58,371
-2,293
-4,105
-45,117
Depreciation and amortization
25,747
26,132
25,016
24,806
Intangible asset impairment charges
54,919
-
0
-
Amortization of premium/discount on marketable securities
340
192
-498
921
Amortization of deferred financing costs and debt discount
-
-
0
-
Change in fair value of contingent consideration
0
2,391
17,759
0
Realized loss (gain) from sale of marketable securities
0
21
-439
-
Realized gains from sales of marketable securities
-
-
-
0
Share-based compensation expense
8,640
8,480
9,651
7,825
Deferred income tax benefit
-16,949
5,916
19,003
-2,645
Noncash lease expense
2,196
2,258
7,980
-
Inventory valuation write-down
4,049
1,815
698
-239
Payment of contingent consideration
22,208
0
9,800
-4,900
Other noncash adjustments, net
-294
-284
5,721
-3,827
Accounts receivable
29,474
-5,619
16,419
7,131
Inventories
306
105
4,180
12,940
Prepaid expenses and other assets
-21,659
12,432
6,905
11,144
Accrued product returns and rebates
9,124
28,623
-23,362
3,543
Accounts payable and other liabilities
-3,790
49
-491
-21,528
Net cash provided by operating activities
-4,810
66,524
19,861
-61,664
Acquisition of sage, net of cash acquired
-
-
0
293,093
Purchases of marketable securities
50,000
78,438
90,200
126,628
Maturities of marketable securities
57,662
59,220
39,317
468,556
Purchases of property and equipment
568
0
427
129
Net cash provided by (used in) investing activities
7,094
-19,218
-51,310
48,706
Proceeds from credit line
-
-
0
-
Payments on credit line
-
-
0
-
Payment on convertible notes
-
-
0
-
Proceeds from issuance of common stock
4,123
13,670
8,557
23,741
Employee taxes paid related to net share settlement of equity awards
88
4,555
31
811
Payment of contingent consideration
11,235
0
0
1,862
Net cash provided by (used in) financing activities
-7,200
9,115
8,526
21,068
Net change in cash, cash equivalents, and restricted cash
-4,916
56,421
-22,923
8,110
Cash, cash equivalents, and restricted cash at beginning of period
186,319
129,898
152,821
69,331
Cash, cash equivalents, and restricted cash at end of period
181,403
186,319
129,898
152,821
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$57,662K
(-78.37%↓ Y/Y)
Net cash provided by
(used in) investing...
$7,094K
(5.72%↑ Y/Y)
Canceled cashflow
$50,568K
Net change in cash,
cash equivalents,...
-$4,916K
(-106.52%↓ Y/Y)
Canceled cashflow
$7,094K
Proceeds from issuance of
common stock
$4,123K
(-22.47%↓ Y/Y)
Intangible asset
impairment charges
$54,919K
Depreciation and
amortization
$25,747K
(-38.32%↓ Y/Y)
Prepaid expenses and
other assets
-$21,659K
(-344.74%↓ Y/Y)
Accrued product returns
and rebates
$9,124K
(-25.28%↓ Y/Y)
Share-based compensation
expense
$8,640K
(-44.53%↓ Y/Y)
Inventory valuation
write-down
$4,049K
(176.01%↑ Y/Y)
Noncash lease expense
$2,196K
Other noncash
adjustments, net
-$294K
(92.22%↑ Y/Y)
Purchases of marketable
securities
$50,000K
(-80.70%↓ Y/Y)
Purchases of property and
equipment
$568K
(-27.37%↓ Y/Y)
Net cash provided by
(used in) financing...
-$7,200K
(64.82%↑ Y/Y)
Canceled cashflow
$4,123K
Net cash provided by
operating activities
-$4,810K
(-105.40%↓ Y/Y)
Canceled cashflow
$126,628K
Total revenues
$219,058K
(-30.52%↓ Y/Y)
Payment of contingent
consideration
$11,235K
(-49.83%↓ Y/Y)
Employee taxes paid
related to net share...
$88K
(-97.40%↓ Y/Y)
Net earnings (loss)
-$58,371K
(-646.95%↓ Y/Y)
Canceled cashflow
$219,058K
Accounts receivable
$29,474K
(2465.49%↑ Y/Y)
Payment of contingent
consideration
$22,208K
(-0.84%↓ Y/Y)
Deferred income tax
benefit
-$16,949K
(-51.98%↓ Y/Y)
Accounts payable and
other liabilities
-$3,790K
(-48.80%↓ Y/Y)
Amortization of
premium/discount on marketable...
$340K
(-69.26%↓ Y/Y)
Inventories
$306K
(103.18%↑ Y/Y)
Other segment items
$80,660K
(104.32%↑ Y/Y)
Selling expenses
$68,910K
(-20.80%↓ Y/Y)
General and
administrative expenses
$40,846K
(-25.85%↓ Y/Y)
Cost of revenues
$33,669K
(3.31%↑ Y/Y)
Total research and
development expenses
$29,463K
(-39.92%↓ Y/Y)
Marketing expenses
$23,881K
(-42.31%↓ Y/Y)
Total external
development program...
$18,864K
(-33.97%↓ Y/Y)
Internal
employee-related expenses
$10,599K
(-48.23%↓ Y/Y)
SPN817
$6,943K
(-1.05%↓ Y/Y)
Early Stage Program
And Other
$5,102K
(-23.76%↓ Y/Y)
SPN820
$2,968K
(-57.37%↓ Y/Y)
Qelbree
$2,217K
(-66.60%↓ Y/Y)
SPN443
$1,046K
ONAPGO
$515K
(-59.16%↓ Y/Y)
ZURZUVAE
$73K
Buy us a coffee
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)